The U.S. Food and Drug Administration (FDA) recently approved the cancer drug olaparib (Lynparza) for the treatment of people with high-risk early breast cancer. Olaparib, which was previously approved for the treatment of certain metastatic cancers, has been studied extensively in ovarian cancer, Nancy Chan, MD, director of breast cancer clinical research at NYU Langone Health’s Perlmutter Cancer Center, tells Verywell Health.
“This is a treatment approach to further reduce the risk of recurrence in this high-risk population,” says Dr. Chan, a member of the faculty in the Department of Medicine at NYU Grossman School of Medicine. “It is overall well tolerated because it is not chemotherapy.”
Read more from Verywell Health.